Palvella Therapeutics, Inc.
PVLA
$23.44
-$1.13-4.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 102.69% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 24.54% | -- | -- | -- | |
| Operating Income | -24.54% | -- | -- | -- | |
| Income Before Tax | -170.48% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -170.48% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -170.48% | -- | -- | -- | |
| EBIT | -24.54% | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -427.54% | -- | -- | -- | |
| Normalized Basic EPS | -704.97% | -- | -- | -- | |
| EPS Diluted | -428.69% | -- | -- | -- | |
| Normalized Diluted EPS | -740.15% | -- | -- | -- | |
| Average Basic Shares Outstanding | 23.13% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 22.51% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |